AstraZeneca cancer pipeline seen as draw for Pfizer
April 21, 2014 at 07:20 AM EDT
LONDON (Reuters) - Pfizer may come back to bid for British drug company AstraZeneca after its reported 60 billion pound ($101 billion) takeover approach was rejected, since a deal could make sense for the U.S. pharmaceuticals giant as it seeks to build up its cancer franchise.
